免疫组化评价CD133在结肠癌组织中的表达率及其与结肠癌预后的关系

IF 1.1 Q4 IMMUNOLOGY Immunopathologia Persa Pub Date : 2023-02-17 DOI:10.34172/ipp.2023.35458
MH. Sanei, Tina Foodeh, M. Sanei
{"title":"免疫组化评价CD133在结肠癌组织中的表达率及其与结肠癌预后的关系","authors":"MH. Sanei, Tina Foodeh, M. Sanei","doi":"10.34172/ipp.2023.35458","DOIUrl":null,"url":null,"abstract":"Introduction: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related death, worldwide. Objectives: This study aimed to evaluate the CD133 expression rate in colon cancers and determine its relationship with colon cancer prognosis. Patients and Methods: This cross-sectional study was conducted in AL-Zahra hospital in Isfahan from April 2008 to April 2014 on 80 patients with CRC. In this study demographic profile such as age and gender, clinicopathologic profile including tumor grade, size, stage, metastasis, 5-year survival and their relation with CD133 expression in form of diffuse, weakly and negative were investigated. Results: From the 80 investigated patients, 47 (58.8%) were male and rest were female. The most common type of CD133 was diffuse type with the 43.8% of cases. Mean age of patients was 61.4 ±14.12 years. This study showed a significant difference between type of CD133 in regards of tumour size (from 23.11 mm in negative cases to 38.85 in weakly cases, P = 0.047). Moreover, the 5-year survival in the three groups of CD133 were significantly different (from 22.54 months in diffuse to 34.42 months in negative cases, P = 0.025). Conclusion: CD133 may be considered as an important tumor marker and a prognostic and diagnostic marker, as well as a therapeutic approach in patients with CRC.","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2023-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of CD133 expression rate in colon cancers with immunohistochemistry method and its relationship with colon cancer prognosis\",\"authors\":\"MH. Sanei, Tina Foodeh, M. Sanei\",\"doi\":\"10.34172/ipp.2023.35458\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related death, worldwide. Objectives: This study aimed to evaluate the CD133 expression rate in colon cancers and determine its relationship with colon cancer prognosis. Patients and Methods: This cross-sectional study was conducted in AL-Zahra hospital in Isfahan from April 2008 to April 2014 on 80 patients with CRC. In this study demographic profile such as age and gender, clinicopathologic profile including tumor grade, size, stage, metastasis, 5-year survival and their relation with CD133 expression in form of diffuse, weakly and negative were investigated. Results: From the 80 investigated patients, 47 (58.8%) were male and rest were female. The most common type of CD133 was diffuse type with the 43.8% of cases. Mean age of patients was 61.4 ±14.12 years. This study showed a significant difference between type of CD133 in regards of tumour size (from 23.11 mm in negative cases to 38.85 in weakly cases, P = 0.047). Moreover, the 5-year survival in the three groups of CD133 were significantly different (from 22.54 months in diffuse to 34.42 months in negative cases, P = 0.025). Conclusion: CD133 may be considered as an important tumor marker and a prognostic and diagnostic marker, as well as a therapeutic approach in patients with CRC.\",\"PeriodicalId\":13454,\"journal\":{\"name\":\"Immunopathologia Persa\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-02-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunopathologia Persa\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/ipp.2023.35458\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunopathologia Persa","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/ipp.2023.35458","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介:癌症(CRC)是全球第三大最常见的癌症,也是癌症相关死亡的第二大原因。目的:本研究旨在评估CD133在结肠癌中的表达率,并确定其与结肠癌癌症预后的关系。患者和方法:这项横断面研究于2008年4月至2014年4月在伊斯法罕的AL Zahra医院对80名CRC患者进行。在本研究中,研究了年龄和性别等人口统计学特征,包括肿瘤分级、大小、分期、转移、5年生存率等临床病理特征,以及它们与CD133以弥漫、弱和阴性形式表达的关系。结果:80例患者中,47例(58.8%)为男性,其余为女性。CD133最常见的类型为弥漫型,占43.8%。患者平均年龄为61.4±14.12岁。本研究显示CD133类型在肿瘤大小方面存在显著差异(阴性病例为23.11mm,弱病例为38.85,P=0.047)。此外,三组CD133的5年生存期有显著差异(从弥漫性病例的22.54个月到阴性病例的34.42个月,P=0.025)。结论:CD133可作为CRC患者的重要肿瘤标志物、预后和诊断标志物以及治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evaluation of CD133 expression rate in colon cancers with immunohistochemistry method and its relationship with colon cancer prognosis
Introduction: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related death, worldwide. Objectives: This study aimed to evaluate the CD133 expression rate in colon cancers and determine its relationship with colon cancer prognosis. Patients and Methods: This cross-sectional study was conducted in AL-Zahra hospital in Isfahan from April 2008 to April 2014 on 80 patients with CRC. In this study demographic profile such as age and gender, clinicopathologic profile including tumor grade, size, stage, metastasis, 5-year survival and their relation with CD133 expression in form of diffuse, weakly and negative were investigated. Results: From the 80 investigated patients, 47 (58.8%) were male and rest were female. The most common type of CD133 was diffuse type with the 43.8% of cases. Mean age of patients was 61.4 ±14.12 years. This study showed a significant difference between type of CD133 in regards of tumour size (from 23.11 mm in negative cases to 38.85 in weakly cases, P = 0.047). Moreover, the 5-year survival in the three groups of CD133 were significantly different (from 22.54 months in diffuse to 34.42 months in negative cases, P = 0.025). Conclusion: CD133 may be considered as an important tumor marker and a prognostic and diagnostic marker, as well as a therapeutic approach in patients with CRC.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
65
审稿时长
3 weeks
期刊最新文献
Investigation of the level of agreement between bone mineral density and trabecular bone score regarding gender, age and body mass index The effectiveness of gabapentin in treating overactive bladder: a quasi-experimental study Association of viral load and autophagy-related genes polymorphisms with hepatitis B virus pre-core/core mutations in chronic hepatitis B virus Iraqi patients Impact of COVID-19 on renal transplant recipients Impact of analgesics on the risk of ovarian cancer; a systematic review and meta-analysis of cohort and case-control studies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1